IMAGE

Figure 7—figure supplement 1.

ID: ZDB-IMAGE-220326-22
Publication: Vasileva et al., 2022 - Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth
All Figures: Figures for Vasileva et al., 2022

Image

Figure Caption

Figure 7—figure supplement 1. Targeting ERK signaling pathway in embryonic model of Ewing sarcoma.

(A) Survival rate of embryos during the first 100 hr of treatment with surfen (0.2 and 1 μM), trametinib (1, 10, and 20 μM), or DMSO. (B) Immunoblot confirming the level of pERK1/2 in embryos treated with 0.2 μM surfen, 1 μM trametinib, or DMSO. (C) Immunofluorescence staining of 48 hpf zebrafish embryos for pERK1/2 (red), and EWSR1-FLI1 (green) after treatment with surfen, trametinib, or DMSO for 24 hr. (D) Surfen and trametinib inhibit the development of EWSR1-FLI1-driven outgrowths in zebrafish larvae. Error bars represent standard error of the mean (SEM), N = 3, **p < 0.01, ***p < 0.001 based on one-way analysis of variance (ANOVA) test.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Elife